KemPharm Stock News

CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced

KemPharm Inc. (NASDAQ:KMPH) traded at $8.31 at close of the session on Monday, 12/20/21, made an upward move of 6.81% on its previous days price. Looking at the stock we see that its previous close was $7.78 and the beta (5Y monthly) reads 3.21 with the days price range being $7.66 $8.91. In terms Insider Trading At KemPharm Inc. (NASDAQ: KMPH): What Did We Note? Read More »

CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced

Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effect

Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS ® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announ

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced its common stock has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with an annual reconstitution of the index. KemPharm’s inclusion in the Nasdaq Biotechnology Index will become effective prior to market open on Monday, December 20, 2021.

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announ

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has been named the 2021 David J. Gury Company of the Year by BioFlorida. The award, presented during the 2021 BioFlorida Annual Conference, is in recognition of the U.S. Food and Drug Administration’s (FDA) approval of AZSTARYS ® for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older, and other important milestones achieved by KemPharm over the past year. Corium, Inc. is leading all commercialization efforts for AZSTARYS in the U.S.

KemPharm Inc. (NASDAQ:KMPH) concluded the trading at $7.72 on Friday, December 03 with a fall of -6.08% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $8.22 and 5Y monthly beta was reading 3.21 with its price kept floating in the range KemPharm Inc. (KMPH): Major Improvements, Worth A Look Read More »

Belvedere Trading LLC reduced its stake in shares of KemPharm, Inc. (NASDAQ:KMPH) by 36.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,996 shares of the specialty pharmaceutical companys stock after selling 10,504 shares during the period. Belvedere []

KemPharm, Inc. (NASDAQ:KMPH) Director David S. Tierney acquired 2,000 shares of the companys stock in a transaction dated Tuesday, November 30th. The stock was purchased at an average cost of $7.79 per share, with a total value of $15,580.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is []

KemPharm, Inc. (NASDAQ:KMPH) Chairman Richard W. Pascoe purchased 1,500 shares of KemPharm stock in a transaction that occurred on Tuesday, November 30th. The stock was acquired at an average cost of $7.88 per share, with a total value of $11,820.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed []

Nuveen Asset Management LLC acquired a new position in shares of KemPharm, Inc. (NASDAQ:KMPH) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 110,717 shares of the specialty pharmaceutical companys stock, valued at approximately $1,419,000. Several other hedge funds []